[7] Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody,
in Patients with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL). Retrieved December 10, 2019, from https://investor.regeneron.com/static-files/75b23b0f-a2e0-4132-96b5-ef7e1387b4da
[6] Forty Seven ASH Investor Event. Retrieved December 10, 2019, from https://ir.fortyseveninc.com/static-files/781777a7-5fcb-43f2-921d-d753ec4de29b
[7] Off-the-shelf Cell-based Cancer Immunotherapy Developing First-of-kind Cell Products using Clonal Master iPSC Lines. Retrieved December 10, 2019, from https://ir.fatetherapeutics.com/static-files/2994778c-fbc3-430d-9658-58a4e0d7501a
[8] Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting. Retrieved December 10, 2019, from https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-presents-its-first-shelf-ipsc-derived-car-t
[9] Off-the-shelf Cell-based Cancer Immunotherapy Developing First-of-kind Cell Products using Clonal Master iPSC Lines. Retrieved December 10, 2019, from https://ir.fatetherapeutics.com/static-files/6de763ae-40aa-4629-a0d6-215492f43f94
[10] Syros Corporate Presentation, December. Retrieved December 10, 2019, from https://d1io3yog0oux5.cloudfront.net/_924eb344af5f69bb9f04b4780f418a9f/syros/db/298/2215/pdf/Syros+Corporate+Deck+12.02.19+Final.pdf
[11] R&D Update and 2019 ASH Data Review. Retrieved December 11, 2019, from https://ir.genmab.com/static-files/60467b61-f6ed-4196-ae15-455d57d9f919
[12] Forty Seven ASH Event. Retrieved December 11, 2019, from https://ir.fortyseveninc.com/static-files/781777a7-5fcb-43f2-921d-d753ec4de29b
原标题:ASH盘点 | CAR-T疗法vs.双特异性抗体疗法;哪些突破可能改变现有治疗模式?
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。
▽关注【药明康德
小编推荐:
中国养生网()
中科建都试管咨询中心:有哪些情
NASH新药获FDA快速通道资格认定
振东制药“秃然”反悔 杀疯了的
萌蒂10亿美元出售中国业务?盘点